Recombinant receptor activator of nuclear factor κB exhibits more marked inhibitory effects on osteoclasts compared with recombinant osteoprotegerin in vitro and in vivo

Xiong,Qi; Xin,Lingli; Zhang,Licheng; Tang,Peifu; Zhang,Lihai

doi:10.3892/mmr.2015.3407

Recombinant receptor activator of nuclear factor κB exhibits more marked inhibitory effects on osteoclasts compared with recombinant osteoprotegerin in vitro and in vivo

Authors:
- Qi Xiong
- Lingli Xin
- Licheng Zhang
- Peifu Tang
- Lihai Zhang
View Affiliations

Affiliations: Department of Orthopedics, General Hospital of Chinese PLA, Beijing 100853, P.R. China, Department of Obstetrics and Gynecology, The Second Artillery General Hospital of Chinese PLA, Beijing 100088, P.R. China
Published online on: March 3, 2015 https://doi.org/10.3892/mmr.2015.3407
Pages: 631-638

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to compare the osteoclast‑inhibiting ability of recombinant osteoprotegerin (OPG) protein (rhOPG‑Fc) and recombinant receptor activator of nuclear factor κB (rhRANK) in vitro and in vivo. Osteoclasts were cultured with either rhOPG‑Fc or rhRANK for 9 days. The number of tartrate‑resistant acid phosphatase (TRAP)‑positive multinucleated cells and resorption pits in bone slices were then counted. In the in vivo investigation, female mice were bilaterally ovariectomized (OVX) and intraperitoneally injected with 3 mg/kg rhOPG‑Fc or rhRANK for 12 weeks, respectively. Bone metabolism, bone mineral density and microstructure changes were then evaluated. The number of TRAP‑positive cells and bone resorption pits decreased significantly following culture with either rhOPG‑Fc or rhRANK, and this was more marked following culture with rhRANK compared with rhOPG‑Fc. The levels of calcium and alkaline phosphatase in the serum were similar pre‑OVX and after 12 weeks of treatment, while the levels of phosphorus in the serum were higher following treatment with rhRANK compared with rhOPG. The bone mineral density (BMD) of the whole body, femoral neck and L4 lumbar vertebral body in the mice treated with either rhOPG‑Fc or rhRANK increased markedly. In addition, the mice treated with rhRANK exhibited significantly higher BMD in the femoral neck and lumbar vertebral body compared with those treated with rhOPG‑Fc. Microcomputed tomography analysis demonstrated that the mice treated with rhRANK exhibited an increased bone volume and structure model index, and decreased trabecular spacing compared with those treated with rhOPG‑Fc. rhRANK increased the inhibition of osteoclast differentiation and bone resorption, and rescued OVX‑induced osteoporosis more effectively compared with rhOPG‑Fc.

View Figures

View References

1	Manolagas SC: Birth and death of bone cells: Basic regulatory mechanisms and implications for the pathogenesis and treatment of osteroporosis. Endocr Rev. 21:115–137. 2000.PubMed/NCBI
2	Takayanagi H: Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol. 7:292–304. 2007. View Article : Google Scholar : PubMed/NCBI
3	Deal C: Bone loss in rheumatoid arthritis: systemic, periarticular, and focal. Curr Rheumatol Rep. 14:231–237. 2012. View Article : Google Scholar : PubMed/NCBI
4	Geusens P and Lems WF: Osteoimmunology and osteoporosis. Arthritis Res Ther. 13:2422011. View Article : Google Scholar : PubMed/NCBI
5	Yasuda H: RANKL, a necessary chance for clinical application to osteoporosis and cancer-related bone diseases. World J Orthod. 4:207–217. 2013. View Article : Google Scholar
6	Kawai M, Mödder UI, Khosla S and Rosen CJ: Emerging therapeutic opportunities for skeletal restoration. Nat Rev Drug Discov. 10:141–156. 2011. View Article : Google Scholar : PubMed/NCBI
7	Mizuno A, Amizuka N, Irie K, et al: Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun. 247:610–615. 1998. View Article : Google Scholar : PubMed/NCBI
8	Khosla S: Minireview: the OPG/RANKL/RANK system. Endocrinology. 142:5050–5055. 2001. View Article : Google Scholar : PubMed/NCBI
9	Weitzmann MN: The Role of Inflammatory Cytokines, the RANKL/OPG Axis, and the Immunoskeletal Interface in Physiological Bone Turnover and Osteoporosis. Scientifica-Cairo. 2013:1257052013.PubMed/NCBI
10	Lacey DL, Timms E, Tan HL, et al: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 93:165–176. 1998. View Article : Google Scholar : PubMed/NCBI
11	Kong YY, Yoshida H, Sarosi I, et al: OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 397:315–323. 1999. View Article : Google Scholar : PubMed/NCBI
12	Pettit AR, Ji H, von Stechow D, et al: TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis. Am J Pathol. 159:1689–1699. 2001. View Article : Google Scholar : PubMed/NCBI
13	Shiotani A, Takami M, Itoh K, Shibasaki Y and Sasaki T: Regulation of osteoclast differentiation and function by receptor activator of NFkB ligand and osteoprotegerin. Anat Rec. 268:137–146. 2002. View Article : Google Scholar : PubMed/NCBI
14	Liu J, Xu K, Wen G, et al: Comparison of the effects of genistein and zoledronic acid on the bone loss in OPG-deficient mice. Bone. 42:950–959. 2008. View Article : Google Scholar : PubMed/NCBI
15	Wang Y, Huang P, Tang PF, Chan KM and Li G: Alendronate (ALN) combined with osteoprotegerin (OPG) significantly improves mechanical properties of long bone than the single use of ALN or OPG in the ovariectomized rats. J Orthop Surg. 6:342011. View Article : Google Scholar
16	Zhang J, Dai J, Yao Z, Lu Y, Dougall W and Keller ET: Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone. Cancer Res. 63:7883–7890. 2003.PubMed/NCBI
17	Oyajobi BO, Anderson DM, Traianedes K, Williams PJ, Yoneda T and Mundy GR: Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy. Cancer Res. 61:2572–2578. 2001.PubMed/NCBI
18	Wang BL, Liang H, Zheng F, Li XX, Liu YB and Dai CL: Recombinant soluble receptor activator of nuclear factor-kappaB inhibits parathyroid hormone-induced osteoclastogenesis in vitro. Sheng Li Xue Bao. 59:169–174. 2007.PubMed/NCBI
19	Tang P, Zhang L, Xu M, Zhang L and Wang Y: Inhibition of the osteoclast activity with the application of recombinant murine RANK protein. Artif Cells Blood Substit Immobil Biotechnol. 38:169–177. 2010. View Article : Google Scholar : PubMed/NCBI
20	Hefley TJ and Stern PH: Isolation of osteoclasts from fetal rat long bones. Calcif Tissue Int. 34:480–487. 1982. View Article : Google Scholar : PubMed/NCBI
21	Anderson DM, Maraskovsky E, Billingsley WL, et al: A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature. 390:175–179. 1997. View Article : Google Scholar : PubMed/NCBI
22	Vitovski S, Phillips JS, Sayers J and Croucher PI: Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways. J Biol Chem. 282:31601–31609. 2007. View Article : Google Scholar : PubMed/NCBI
23	Zhang S, Liu C, Huang P, et al: The affinity of human RANK binding to its ligand RANKL. Arch Biochem Biophys. 487:49–53. 2009. View Article : Google Scholar : PubMed/NCBI
24	French DL, Muir JM and Webber CE: The ovariectomized, mature rat model of postmenopausal osteoporosis: an assessment of the bone sparing effects of curcumin. Phytomedicine. 15:1069–1078. 2008. View Article : Google Scholar : PubMed/NCBI
25	Seibel MJ: Biochemical markers of bone turnover: Part I: Biochemistry and variability. Clin Biochem Rev. 26:97–122. 2005.
26	Szulc P and Bouxsein ML: Overview of osteoporosis: Epidemiology and clinical management. Veterbral Fracture Initiative Resource Document PART I. 2011.
27	Kanis JA, Melton LJ III, Christiansen C, Johnston CC and Khaltaev N: The diagnosis of osteoporosis. J Bone Miner Res. 9:1137–1141. 1994. View Article : Google Scholar : PubMed/NCBI